Physiomics ICSB presentation

RNS Number : 6524B

Physiomics PLC

20 August 2008

 

Physiomics plc

The Magdalen Centre

The Oxford Science Park

Robert Robinson Avenue

Oxford

OX4 4GA

UK

 

Tel [phone]

Fax [phone]

20 August 2008                                    

 

Physiomics plc ('Physiomics' or 'the Company')

Physiomics to present on Chronotherapy at the International Conference on Systems Biology

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that itwill be participating in the 9th International Conference on Systems Biology, taking place at the Gothenburg Convention Centre on 22-28 August 2008. Dr David Orrell, senior scientist at Physiomics, will give an oral presentation entitled “A Systems Biology Approach to Chronotherapy” during the “Drug discovery” session, scheduled at 11:40 am on 24 August. The talk will update results of the Company’s chronotherapy research program, which is part of the EU funded TEMPO (Temporal Genomics for Tailored Chronotherapeutics)project.

More information about the conference may be found at www.icsb-2008.org

For further information:

Physiomics plc                                                     [phone]

Dr Christophe Chassagnole, COO

E-mail: [e-mail]

Grant Thornton Corporate Finance                       [phone]

Philip Secrett, Colin Aaronson

 

 

About TEMPO project (LSHG-CT-2006-037543)

In 2006 Physiomics was selected to participate in the TEMPO Project as one of four Industry partners working closely with four distinguished European academic research groups. The project is coordinated by INSERM unit director Prof Francis Levi, at Paul Brousse hospital in Villejuif (France). TEMPO is a STREP project funded in part by the European Commission through its Life Sciences and Health Sixth Framework programme.

 

This three year programme aims to optimise treatment by exploring the effect of circadian rhythms (the body’s clock) on changes in cell proliferation and the effectiveness of cancer drugs. Physiomics is using its cell simulation technologies to study how cancer drugs affect the cell cycle/circadian clock system behaviour at the cellular level, the cell population level (virtual Fluorescence-Activated Cell-Sortingexperiment), and the tissue level (virtual tumour). Using pharmacokinetics simulations in combination with pharmacodynamics profiles, Physiomics will help establish one or more physiologically relevant drug regimes and delivery schedules.

 

Physiomics will receive approximately £169,000 (€252,650) of matched funding over the three year period and if successful will share in 3 to 5 new therapeutic schedules according to the patient profiles for 2 main drug classes against cancer and more specifically colorectal cancer. TEMPO develops tools that will enable to select the best administration schedule for anti-cancer drugs, taking into account the genes expression profile of the patient. Under temporal control of the drug administration, the efficacy as well as the toxicity will be controlled in an optimised manner.

 

For further information, please visit www.chrono-tempo.org

 

About Physiomics plc

Physiomics plc (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. As 80-90 per cent of all clinical drug candidates fail to reach the market, estimates1 show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million.

Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating most important molecular events taking place during the human cell cycle and apoptosis processes. Physiomics developed SystemCell® technology, a multi-cellular environment software, which enables the simulation of population of 'virtual cells'.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com

 

SystemCell® is a registered trademark of Physiomics plc

1Tufts Centre Impact Report 2002

 

 

 

END

 

 

NRAFKCKQNBKDPFD